Accueil>>Signaling Pathways>> Others>>Gemcabene

Gemcabene (Synonyms: PD-72953)

Catalog No.GC36128

Le gemcabène (PD-72953), un agent hypolipidémiant premier de sa catégorie, abaisse le cholestérol des lipoprotéines de basse densité (LDL-C), diminue les triglycérides et augmente le cholestérol des lipoprotéines de haute densité (HDL-C) et abaisse les pro-inflammatoires protéine de phase aiguë, protéine C-réactive (CRP), exerÇant une activité anti-inflammatoire.

Products are for research use only. Not for human use. We do not sell to patients.

Gemcabene Chemical Structure

Cas No.: 183293-82-5

Taille Prix Stock Qté
10mM (in 1mL DMSO)
104,00 $US
En stock
1mg
36,00 $US
En stock
5mg
95,00 $US
En stock
10mg
158,00 $US
En stock
50mg
473,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity[1][2][3].

Gemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2)[3].

[1]. Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. [2]. Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471. [3]. Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568.

Avis

Review for Gemcabene

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gemcabene

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.